Adaptive Biotechnologies Plans to Split Its MRD and Immune Medicine Units
The company expects to decide the best path by year-end 2026.
/ 4 items
#ADPT↓
Biotech Earnings Preview: Mixed Results Send Stocks on Divergent Paths
Nuvation Bio and Sarepta shares tumble on disappointing preliminary results while Adaptive Biotechnologies surges on strong revenue beat.
Adaptive Biotechnologies Partners with Pfizer on Immune Disease Research
Adaptive Biotechnologies signs two deals with Pfizer worth up to $890M to discover rheumatoid arthritis treatments and share immune system data for AI-powered drug development.
Adaptive: Why Analysts See It as a Dominant Force
Guggenheim rated ADPT a "Buy." It dominates blood cancer testing and will see major growth. "Shares are currently undervalued."